Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: max who wrote (1668)	4/4/1998 1:15:00 PM
From: JanyBlueEyes	Respond to of 5736

Third-Party Reimbursement Info From the Annual Report (10K) Filed on March 30,1998 In the United States, patients, hospitals and physicians who purchase medical devices, generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to reimburse them for all or a portion of the cost of the medical device. Reimbursement for devices that have received FDA clearance has generally been available in the United States. The Company has obtained confirmation from the Department of Coding of the American Medical Association ("AMA") that the same code used for the reimbursement of laboratory blood tests used to monitor bilirubin infant jaundice is permissible for use in obtaining reimbursement for tests using the Colormate(TM) Bilirubin Device. The Company believes this confirmation will be an important factor in its pricing structure in the United States.......

To: max who wrote (1668)	4/4/1998 1:17:00 PM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

LED Device From the Annual Report (10K) Filed on March 30,1998 The Company has completed both the new housing and related packaging for its Colormate(TM) Bilirubin Device. The Company also recently completed development of the Bilirubin LED Device that could be used for monitoring bilirubin infant jaundice, subject to additional clinical testing and possible further FDA review and clearance. The Company recently received IRB approval from Mt. Sinai Hospital, Elmhurst Hospital and William Beaumont Hospital to commence clinical trials of the Bilirubin LED Device. For non-medical applications, the Colormate(TM) LED Device may be marketed in various industries including the dental, beauty aid and fashion industries and also may be marketed directly to consumers for home and personal use. The Company expects the new LED versions will also be capable of being manufactured at a cost substantially less than the cost incurred in manufacturing the Company's existing Colormate(TM) units.

To: max who wrote (1668)	4/4/1998 1:20:00 PM
From: JanyBlueEyes	Respond to of 5736

Manufacturing From the Annual Report (10K) Filed on March 30,1998 ...One element of the Company's business strategy is to outsource the production of the components and final assembly of the Colormate(TM) Bilirubin Device (including the associated disposable calibration standard components) by subcontracting under arrangements with third-party manufacturers. The Company is presently negotiating with certain third-party manufacturers for the production of the light sensors, disposable calibration standard components and hardware components of the Colormate(TM) Bilirubin Device. The Company believes, although there can be no assurance, that it will be able to outsource the production and assembly of additional Colormate(TM) units, including for custom application use, such as monitoring for bilirubin infant jaundice, at commercially marketable prices. The Company has limited experience in outsourcing the production of such products in the volumes that would be necessary for the Company to achieve significant commercial sales, but demonstrated its ability to do so when it arranged for mass manufacturing of its Colormate(TM) units for Avon. The Company believes, based on discussions with suppliers of components used in its Colormate(TM) Bilirubin Device and published price lists, that the components can be purchased in quantities of 1,000 or more on terms acceptable to the Company. The Company believes that its relations with the parts manufacturers and assemblers of the Colormate(TM) units held in its inventory are good and the Company believes that it will be able to obtain any necessary parts manufacturers or assemblers on terms acceptable to the Company. The Company intends initially to retain the services of one medical device manufacturer in order to subcontract production of the Colormate(TM) Bilirubin Device......